BPC-157 and TB-500 are among the peptides now restored to Category 1
For this reason, treatments such as peptide therapy must always be administered under the supervision of a clinician
Because these medicines are not yet licensed, there are no approved patient information leaflets or UK Summary of Product Characteristics (SmPC) available
Pathological activation of the salience and default networks can interfere with the process of switching between these two networks, which would have a differential impact on mood and memory functionality
5-Amino-1MQ is not FDA approved as a standard treatment for anti-aging, fat loss, insulin resistance, cardiovascular disease, muscle recovery, or general wellness
Legal status (US): BPC-157 has no FDA-approved indication